Pfizer, BioNTech Get $1.95 Billion Covid-19 Vaccine Order From U.S. Government

To Know more how you can benefit from the Muslim Times, go to our Homepage or About Us page

Pfizer and USA

The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.

Source: WSJ

By Chris Wack

Americans would receive the vaccine for free under agreement with government

Pfizer Inc. PFE 0.52% and BioNTech SE BNTX 3.85% said Wednesday they have signed a $1.95 billion agreement with the U.S. Department of Health and Human Services and the Defense Department to secure hundreds of millions of doses of a coronavirus vaccine which Americans would receive for free.

Under the agreement, the U.S. government would receive 100 million doses of BNT162, the Covid-19 vaccine candidate jointly developed by Pfizer and BioNTech, and can acquire up to 500 million additional doses. Pfizer would make the vaccine.

The BNT162 program is based on BioNTech’s proprietary mRNA technology and supported by Pfizer’s global vaccine development and manufacturing capabilities. The BNT162 vaccine candidates are undergoing clinical studies and aren’t currently approved for distribution anywhere in the world.

The Pfizer-BioNTech vaccine development program is evaluating at least four experimental vaccines. If the studies are successful, Pfizer and BioNTech expect to seek emergency use authorization or some form of regulatory approval as early as October.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

For the latest health news from BBC, Please click here

Novavax starting human trial of its vaccine in Australia

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters


2 replies

  1. Novavax, Inc. (NASDAQ: NVAX), which issued an update on its coronavirus vaccine program earlier this week, announced late Thursday a manufacturing agreement with a CDMO, while also flagging a slightly delay in the Phase 1 readout.

    Novavax’ Deal With Fujifilm: Novavax, which is working on an investigational vaccine (codenamed NVX-CoV2373) against the SARS-CoV2, said it struck a manufacturing deal with Fujifim Diosynth Biotechnologies for manufacturing bulk drug substance for the vaccine candidate.

    The companies said Fujifilm’s site in Morrisville, North Carolina has begun production of the first batch of NVX-CoV2373.

    The agreement draws upon the $1.6 billion funding award Novavax was granted under the federal’s government’s Operation Warp Speed project.

    Related Link: 5 Coronavirus Stock Valuations Surging During The Pandemic

    The companies said the batches produced at Fujifilm’s site in North Carolina will be used in a future pivotal Phase 3 clinical trial of up to 30,000 subjects, which will determine the safety and efficacy of NVX-CoV2373. The trial is set to start in the fall.

    “We are grateful to partner with the team at FUJIFILM Diosynth Biotechnologies to ensure the large-scale manufacture of our COVID-19 vaccine candidate,” said Stanley Erck, CEO of Novavax.

  2. Microsoft founder and billionaire philanthropist Bill Gates said therapeutic drugs to treat the coronavirus could reduce the death rate substantially by the end of this year but a vaccine will be crucial to bringing back a sense of normalcy to the society.

    “You can see the therapeutic benefit faster than the protective benefit,” Gates said in an interview that aired Tuesday on CNBC’s “Squawk Box.” “So I think there’s a good chance we’ll have substantial death rate reduction by the end of the year with the combination of those new tools.”

    The co-founder of Microsoft and co-chair of the Bill and Melinda Gates Foundation said remdesivir was one of the leading treatments in the therapeutic research. Remdesivir is an antiviral drug from Gilead Sciences that has shown to have reduced the risk of death for severely sick Covid-19 patients by 62% compared with standard care alone.

    Gates said there are two other antivirals that scientists are looking into, which can be administered orally instead of being injected with an IV like the remdesivir treatment.

    The Bill and Melinda Gates Foundation announced plans in February to donate $100 million to vaccine research and treatment efforts for the coronavirus as part of the World Health Organization’s request for $675 million in contributions to fight the spread of the virus. In June, the foundation pledged an additional $1.6 billion to the Gavi vaccine alliance, an organization focused on efforts to immunize children amid the coronavirus pandemic.

    “Also I’d say monoclonal antibodies are probably the most promising class …You have people like Regeneron, Eli Lilly and AstraZeneca doing some pretty strong work,” Gates added.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.